BIIB 023
Alternative Names: Anti-TWEAK monoclonal antibody - Biogen; BIIB-023Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Biogen Idec
- Developer Biogen
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action TNFSF12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Muscular atrophy
- Discontinued Lupus nephritis; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Muscle-wasting(In volunteers) in USA (IV, Infusion)
- 26 Oct 2015 Discontinued - Phase-I for Rheumatoid arthritis in Russia, Ukraine, USA (IV)
- 26 Oct 2015 Discontinued - Preclinical for Rheumatoid arthritis in USA (SC)